Want to see NKTR full AI Analyst Report?
NKTR Stock Chart & Stats
$73.77
$0.30(0.42%)
At close: 4:00 PM EDT
$73.77
$0.30(0.42%)
Day’s Range― - ―
52-Week Range$33.40 - $109.00
Previous CloseN/A
Volume103.19K
Average Volume (3M)1.66M
Market Cap
$1.34B
Enterprise Value$1.76B
Total Cash (Recent Filing)$684.34M
Total Debt (Recent Filing)$135.93M
Price to Earnings (P/E)―
Beta3.57
Next Earnings
Nov 05, 2026EPS Estimate
-2.07Next Dividend Ex-DateN/A
Dividend YieldN/A
Share Statistics
EPS (TTM)-6.70
Shares Outstanding34,142,994
10 Day Avg. Volume1,278,747
30 Day Avg. Volume1,662,893
Financial Highlights & Ratios
PEG Ratio-0.36
Price to Book (P/B)7.94
Price to Sales (P/S)12.91
P/FCF Ratio-3.42
Enterprise Value/Market Cap1.31
Enterprise Value/Revenue32.23
Enterprise Value/Gross Profit32.43
Enterprise Value/Ebitda-13.11
Forecast
1Y Price Target
$132.45Price Target Upside79.55% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering14
EPS Forecast (FY)-8.03
Revenue Forecast (FY)$42.00M
Bulls Say, Bears Say
Bulls Say
Durable Clinical DifferentiationRezpegaldesleukin’s reported durability and potential for less frequent maintenance could distinguish it in alopecia areata and atopic dermatitis. If confirmed in Phase 3, durable responses may support stronger physician adoption, differentiated positioning, and a more sustainable commercial profile.
Late-Stage Pipeline ProgressProgress into pivotal trials materially advances the lead asset toward potential regulatory submission in major immune dermatology indications. The programs provide a clearer development path and create multiple opportunities for future product revenue if efficacy and safety results support approval.
Strong Cash PositionThe substantial cash balance and stated runway give Nektar funding capacity to execute its expanding Phase 3 program without an immediate financing requirement. This supports clinical continuity, preserves strategic flexibility, and allows the company to pursue important readouts before potential commercialization.
Bears Say
Heavy Cash BurnNektar is consuming substantial cash while its pipeline remains pre-commercial, making continued funding dependent on its existing reserves, financing, or future partnership proceeds. Persistent burn can reduce flexibility and increase dilution or financing risk before products generate recurring revenue.
Limited Near-Term RevenueRevenue remains modest and concentrated in royalty income rather than sales from an approved internal product. Until rezpegaldesleukin or another asset reaches commercialization, the company lacks a recurring product-revenue base to offset development expenses and support durable self-funded growth.
Long Development And Regulatory RiskNektar’s principal value creation milestones remain several years away and depend on successful pivotal trials, regulatory interactions, and eventual approval. Delays, unfavorable data, or changing competitive conditions could extend losses and require more capital before commercial returns are realized.
Nektar Therapeutics News
NKTR FAQ
What was Nektar Therapeutics’s price range in the past 12 months?
Nektar Therapeutics lowest stock price was $33.40 and its highest was $109.00 in the past 12 months.
What is Nektar Therapeutics’s market cap?
Nektar Therapeutics’s market cap is $1.34B.
When is Nektar Therapeutics’s upcoming earnings report date?
Nektar Therapeutics’s upcoming earnings report date is Nov 05, 2026 which is in 13 days.
How were Nektar Therapeutics’s earnings last quarter?
Nektar Therapeutics released its earnings results on Aug 13, 2026. The company reported -$1.23 earnings per share for the quarter, beating the consensus estimate of -$1.971 by $0.741.
Is Nektar Therapeutics overvalued?
According to Wall Street analysts Nektar Therapeutics’s price is currently Undervalued.
Does Nektar Therapeutics pay dividends?
Nektar Therapeutics does not currently pay dividends.
What is Nektar Therapeutics’s EPS estimate?
Nektar Therapeutics’s EPS estimate is -2.07.
How many shares outstanding does Nektar Therapeutics have?
Nektar Therapeutics has 34,142,994 shares outstanding.
What happened to Nektar Therapeutics’s price movement after its last earnings report?
Nektar Therapeutics reported an EPS of -$1.23 in its last earnings report, beating expectations of -$1.971. Following the earnings report the stock price went down -3.82%.
Which hedge fund is a major shareholder of Nektar Therapeutics?
Currently, no hedge funds are holding shares in NKTR
What is the TipRanks Smart Score and how is it calculated?
Smart Score combines eight research factors - such as analyst recommendations, hedge fund trends, and technical indicators - to measure a stock’s outlook. These signals are unified into a single score that reflects bullish or bearish momentum. See detailed methodology
Nektar Therapeutics Stock Smart Score
Neutral
1
2
3
4
5
6
7
8
9
10
Analyst Consensus
Moderate Buy
Average Price Target:
$132.45 (79.55% Upside)
$132.45 (79.55% Upside)
Blogger Sentiment
Bullish
NKTR Sentiment 71%
Sector Average 66%
Sector Average 66%
Hedge Fund Trend
Increased
By 443.6K Shares
Last Quarter.
Last Quarter.
Insider Transactions
Sold Shares
Worth $43.5K over
the Last 3 Months
the Last 3 Months
Crowd Wisdom
Very Positive
Last 7 Days ▼ 1.0%
Last 30 Days ▲ 5.4%
Last 30 Days ▲ 5.4%
News Sentiment
Very Bullish
Bullish news 100%
Bearish news 0%
Bearish news 0%
Technicals
SMA
Negative
20 days / 200 days
Momentum
-35.55%
12-Months-Change
Fundamentals
Return on Equity
-37.99%
Trailing 12-Months
Asset Growth
427.69%
Trailing 12-Months
Learn more about TipRanks Smart Score
Company Description
Nektar Therapeutics
Nektar Therapeutics is a biopharmaceutical firm dedicated to the global discovery and advancement of therapies addressing significant unmet medical requirements. Central to its robust pipeline is Bempegaldesleukin, a CD122-preferential interleukin-2 (IL-2) pathway agonist. This drug is currently in Phase 3 clinical trials for metastatic melanoma, renal cell carcinoma, muscle-invasive bladder cancer, head and neck squamous cell carcinoma, and adjuvant melanoma. It is also being evaluated in Phase 2 for renal cell carcinoma, non-small cell lung cancer, and urothelial cancer; Phase 1/2A for head and neck squamous cell carcinoma; Phase 1/2 for various solid tumors; and Phase 1B for COVID-19. Additionally, Nektar is developing NKTR-358, a cytokine Treg stimulant, which is in Phase 2 trials for systemic lupus erythematosus and ulcerative colitis, and Phase 1B for atopic dermatitis and psoriasis. Their portfolio further includes NKTR-255, an IL-15 receptor agonist, undergoing Phase 1/2 trials for non-Hodgkin's lymphoma, multiple myeloma, head and neck cancer, and colorectal cancer. Another investigational compound, NKTR-262, a toll-like receptor agonist, is in Phase 1/2 trials for solid tumors. The company is also advancing several other drug candidates. Nektar Therapeutics maintains strategic collaboration agreements with a multitude of pharmaceutical entities, including Takeda Pharmaceutical Company Ltd., AstraZeneca AB, UCB Pharma S.A., F. Hoffmann-La Roche Ltd, Bausch Health Companies Inc., Pfizer Inc., Amgen Inc., UCB Pharma (Biogen), Bristol-Myers Squibb Company, Baxalta Incorporated, Eli Lilly and Company, Merck KGaA, and SFJ Pharmaceuticals, Inc. Established in 1990, Nektar Therapeutics is headquartered in San Francisco, California.
NKTR Earnings Call
Q2 2026
0:00 / 0:00
Earnings Call Sentiment|Positive
The call contained multiple substantial positive developments: initiation of the global Phase 3 program in atopic dermatitis, FDA-aligned registrational design for alopecia areata, strong Phase 2b signals (efficacy, durability, favorable safety), robust cash balance after a $350M offering, and encouraging market research supporting commercial potential. Offsetting these positives are expected higher R&D and G&A spend, a meaningful quarterly net loss, modest near-term revenue largely from non-cash royalties, a cash runway that covers key mid-2028 readouts but leaves limited buffer for delays, and an ongoing litigation matter. On balance the strategic, clinical, and financial highlights outweigh the risks described on the call.View all NKTR earnings summariesNKTR Stock 12 Month Forecast
Average Price Target
$132.45
▲(79.55% Upside)
Technical Analysis
Wave Life Sciences
―
Trevi Therapeutics
―
Oric Pharmaceuticals
―
Nuvation Bio
―
Praxis Precision Medicines
―
Ownership Overview
0.46% Insiders
13.67% Mutual Funds
9.83% Other Institutional Investors
61.59% Public Companies and
Individual Investors